Another targeted cancer drug has been approved in the US following a major improvement in survival for people with metastatic pancreatic cancer. Rasonque (daraxonrasib), was approved by the US Food and Drug Administration (FDA) on 26 August 2026. It’s approved for use in adults with advanced pancreatic adenocarcinoma whose disease has been treated with systemic therapy or who are not candidates for multi-agent systemic treatment.
The approval represents a significant step forward in addressing one of the most challenging cancers to treat. Pancreatic cancer is frequently detected after it has metastasized, and available treatments have traditionally provided limited benefits for many individuals. Daraxonrasib offers a targeted oral therapy intended to disrupt molecular pathways that support the growth and survival of cancer cells.
The FDA’s regulatory approval was based on data from the Phase 3 RASolute 302 trial, which involved 500 adult patients with previously treated metastatic pancreatic adenocarcinoma. The trial randomized patients to treatment with daraxonrasib or treatment with physician’s choice of conventional chemotherapy.
In the primary study, patients on daraxonrasib survived for a median of 13.2 months, compared to 6.7 months of those given chemotherapy. The median progression-free survival the amount of time before worsening of the disease or death was 7.2 months with the new drug, compared to 3.6 months with chemotherapy.
The overall response rate was again higher in the daraxonrasib group at 30% compared to 11% in those treated with chemotherapy alone. These outcomes reflect gains in key efficacy endpoints.
Median survival refers to the time point at which half of the participants in a group have died and half are still alive. This measure does not indicate exactly how long any individual patient will live, and the trial results do not show that the medicine cures pancreatic cancer.
Daraxonrasib is a new type of medicine called RAS(ON) inhibitors. The RAS family of proteins, controls, how, cells, grow, and communicate. Abnormal signals that result in the continued activity of RAS can bring cells dividing and the growth of tumours.
Many pancreatic adenocarcinomas depend on abnormal RAS signalling. Rather than targeting only one specific RAS mutation, daraxonrasib is designed to inhibit multiple forms of active RAS proteins, including several mutant forms connected to cancer.
Patients can take it orally once daily as a substitute for intravenous chemotherapy. The drug blocks various signalling pathways that lead to tumour rapid growth, with the hope of suppressing the disease and prolonging survival.
The FDA prescribing information also covers serious adverse effects that may include gastrointestinal perforation; severe skin reactions; and interstitial lung disease or pneumonitis. These have to be treated and monitored by a doctor who can change or stop the medication as needed.
The researchers also stress the importance of longer follow-up to determine how long these improvements may last and how the medicine’s resistance may develop. Because the clinical trial enrolled patients well enough to take part, the findings may not be relevant to all patients with advanced pancreatic cancer.
